High Throughput Screens

About the High Throughput Screening facility

We are based in the Wolfson Wohl Cancer Research Centre building on the Garscube Estate. We offer assistance, on a collaborative basis, to Centre researchers in designing and undertaking high throughput screening projects.

So that we can understand the goals of your project, its current status and the background information available, please complete a Screening Facility Project Application Form. Please contact Dr Emma Shanks for assistance in completing this form or in designing your project. Once the form is complete, please submit it here.

The next call for Project Outlines closes on 18th August 2017.

Contact details

High throughput screening:
Dr Emma Shanks, e.shanks@beatson.gla.ac.uk

General information and advice:
Dr Liz Musgrove, liz.musgrove@glasgow.ac.uk

Project review process

Completed Project Outlines will be reviewed and ranked by an expert Project Review Panel. Following its recommendations, final project approval will be sought from the Centre Management Board, which meets quarterly. Investigators will be notified of the outcome of their application soon after the Management Board meeting.

Project Review Panel:
Dr Dave Bryant
Dr Vignir Helgason
Dr Daniel Murphy
Dr Liz Musgrove
Prof Jim Norman
Dr Emma Shanks

Important dates

The next call for Project Outlines closes on 18th August 2017.

Project Outlines are considered by the panel and then at a Centre Management Board Meeting.

Completed and current projects

Completed

  • Platform development: a high-throughput, lentiviral shRNA array for analysis of 3-dimensional (3D) spheroid formation - Dave Bryant, University of Glasgow
  • Targeting neurotransmitter pathways: identifying novel therapeutics to eradicate CML stem cells - Tessa Holyoake & David Vetrie, University of Glasgow
  • Identification of NIH-approved oncology drug(s) that can overcome acquired TKI-resistance in chronic myeloid leukaemia - Vignir Helgason, University of Glasgow
  • Screening for essential factors shaping the aggressive ESC/iPSC-like prostate cancer subtype - Elke Markert, University of Glasgow
  • Identification of novel therapeutic avenues for pancreatic cancer using oncogene targeting and FDA approved compound libraries - Andrew Biankin, University of Glasgow

Ongoing

  • Identification of novel therapeutic drugs for new combinational therapies - Hing Leung, Beatson Institute
  • Epigenetic modifiers of immunogenicity in ovarian high grade serous carcinoma - Iain McNeish, University of Glasgow
  • Solute Carrier Family (SLC) targeted screen - Oliver Maddocks, University of Glasgow